TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Telix Pharmaceuticals Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026
$10.74+0.05 (+0.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Telix Pharmaceuticals Ltd revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Precision Medicine | $621.93M | $508.51M | $329.21M | 77.4% | +22.3% |
| Manufacturing Solutions | $172.59M | $1.82M | $277.00K | 21.5% | +9398.7% |
| Therapeutics | $9.27M | $6.23M | $3.50M | 1.2% | +48.9% |
| Operating income | FY2025 | FY2024 | FY2023 | YoY |
|---|---|---|---|---|
| Precision Medicine | $209.55M | $164.26M | $68.73M | +27.6% |
| Manufacturing Solutions | -$23.94M | -$16.53M | -$3.97M | +44.8% |
| Therapeutics | -$98.25M | -$49.90M | -$28.12M | +96.9% |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| United States | $784.91M | $502.76M | $324.47M | 97.7% | +56.1% |
| China | $9.83M | $382.00K | $863.00K | 1.2% | +2474.3% |
| Other countries | $9.06M | $13.41M | $7.64M | 1.1% | -32.5% |
From the segment and revenue-disaggregation notes of Telix Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.